White House unveils TrumpRx.gov to steer patients to discounted drugs

A new White House website, TrumpRx.gov, was unveiled to direct Americans to discounted prescription drugs by linking to pharmaceutical companies’ direct-to-consumer sales channels and providing coupons for use at pharmacies. The administration said the portal is intended to let patients "access large discounts on many of the most popular and highest-priced medicines in the country, paying prices in line with the lowest paid by other developed nations (known as the most‑favored‑nation, or MFN, price)."

White House press secretary Karoline Leavitt posted on X that the site debuted at 7 p.m. ET. The unveiling was presented in a televised White House appearance that administration materials described as an evening event on the White House campus. President Trump told attendees, "You’re going to save a fortune," adding, "This is also so good for overall healthcare" and declaring, "We're tired of subsidizing the world."

TrumpRx.gov does not sell medications directly. Instead, the landing page routes users to participating manufacturers’ purchase platforms or supplies printable or digital coupons that can be presented at pharmacies. A prescription will be required for purchases and must be validated by the pharmacy filling the order, the White House said. The administration said the site launches with more than 40 medicines, including the weight‑loss drugs Ozempic and Wegovy.

The portal is the latest element of the administration’s push to use so‑called most‑favored‑nation pricing, a policy that ties U.S. prices to the lowest prices paid in other developed countries. The White House framed the initiative as the product of a series of recent deals with drugmakers. Administration materials listed major manufacturers among participants and said it had negotiated agreements with a range of companies; officials have not provided public, line‑by‑line terms, saying details of the arrangements are confidential.

Analysts and consumer advocates cautioned that the practical benefits will vary. Research from the Rand Corporation shows U.S. prescription prices run two to three times higher on average than in other developed nations, and in some cases as much as 10 times higher, a gap the administration cited in arguing for MFN-based discounts. But the design of TrumpRx.gov makes it primarily useful for cash-paying consumers who forgo insurance coverage. The administration itself includes an on-site disclaimer noting listed amounts are out‑of‑pocket prices and may be higher than what insured patients pay through their plans.

Officials did not specify how cash purchases through manufacturer portals or pharmacy coupons will interact with private insurance, and the White House has not released the financial details of individual deals. That opacity has prompted concerns among Democrats in Congress, who have questioned the legality of the program and flagged potential conflicts of interest. The administration has said it will continue to expand listings and touted the portal as a new option for patients seeking lower prices.

"You should not be buying drugs anymore going forward without at least checking to see if those medications are available at the discounted prices on TrumpRx.gov," Oz said. The site and the administration's promotional materials encourage shoppers to compare options, while leaving unanswered how broadly the MFN-based discounts will reach Americans who rely on employer or government insurance.